Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPECU: Eculizumab Discontinuation in aHUS
NCT02574403Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Nov 2015
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by CHU de Nantes. Started Nov 2015; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT02574403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574403.